

Summary statistics - data report Version 5.3  
Situation 2022/H2

**3.1 Table: Treatment status at recruitment, by CD4 and year**

|             | Treatment naive |         |         |      | On treatment |         |         |      | Treatment interrupted |         |         |      | Total |
|-------------|-----------------|---------|---------|------|--------------|---------|---------|------|-----------------------|---------|---------|------|-------|
|             | <200            | 200-349 | 350-500 | >500 | <200         | 200-349 | 350-500 | >500 | <200                  | 200-349 | 350-500 | >500 |       |
| <b>2017</b> | 49              | 41      | 50      | 84   | 8            | 15      | 29      | 104  | 0                     | 2       | 4       | 11   | 397   |
| <b>2018</b> | 46              | 38      | 39      | 62   | 7            | 16      | 26      | 106  | 3                     | 3       | 3       | 4    | 353   |
| <b>2019</b> | 50              | 46      | 35      | 72   | 13           | 18      | 22      | 82   | 1                     | 2       | 1       | 6    | 348   |
| <b>2020</b> | 13              | 25      | 20      | 31   | 10           | 13      | 20      | 77   | 3                     | 1       | 1       | 8    | 222   |
| <b>2021</b> | 23              | 28      | 31      | 53   | 5            | 14      | 13      | 88   | 1                     | 2       | 0       | 7    | 265   |
| <b>2022</b> | 37              | 29      | 25      | 30   | 7            | 13      | 12      | 81   | 2                     | 0       | 0       | 10   | 246   |

**3.2 Table: Treatment status at recruitment, by HIV viral load and year**

|             | Treatment naive (copies/ml) |          |              |         | On treatment (copies/ml) |          |              |         | Treatment interrupted (copies/ml) |          |              |         | Total |
|-------------|-----------------------------|----------|--------------|---------|--------------------------|----------|--------------|---------|-----------------------------------|----------|--------------|---------|-------|
|             | 0 - 50                      | 51 - 400 | 401 - 100000 | >100000 | 0 - 50                   | 51 - 400 | 401 - 100000 | >100000 | 0 - 50                            | 51 - 400 | 401 - 100000 | >100000 |       |
| <b>2017</b> | 37                          | 21       | 105          | 60      | 151                      | 8        | 5            | 1       | 8                                 | 0        | 1            | 0       | 397   |
| <b>2018</b> | 32                          | 18       | 89           | 47      | 145                      | 12       | 2            | 2       | 11                                | 0        | 0            | 0       | 358   |
| <b>2019</b> | 34                          | 15       | 86           | 67      | 116                      | 12       | 6            | 2       | 8                                 | 2        | 1            | 0       | 349   |
| <b>2020</b> | 15                          | 4        | 35           | 40      | 113                      | 7        | 6            | 3       | 6                                 | 1        | 1            | 0       | 231   |
| <b>2021</b> | 35                          | 11       | 59           | 34      | 106                      | 13       | 2            | 1       | 6                                 | 1        | 3            | 1       | 272   |
| <b>2022</b> | 17                          | 15       | 46           | 41      | 106                      | 6        | 3            | 1       | 9                                 | 1        | 0            | 1       | 246   |

**3.3 Table: Treatment status of participants under follow-up, by CD4 and year \***

|             | Treatment naive |         |         |      | On treatment |         |         |      | Treatment interrupted |         |         |      | Total |
|-------------|-----------------|---------|---------|------|--------------|---------|---------|------|-----------------------|---------|---------|------|-------|
|             | <200            | 200-349 | 350-500 | >500 | <200         | 200-349 | 350-500 | >500 | <200                  | 200-349 | 350-500 | >500 |       |
| <b>2017</b> | 62              | 55      | 60      | 167  | 201          | 715     | 1598    | 6660 | 19                    | 16      | 30      | 48   | 9631  |
| <b>2018</b> | 58              | 41      | 64      | 113  | 188          | 711     | 1390    | 7015 | 18                    | 21      | 17      | 54   | 9690  |
| <b>2019</b> | 58              | 51      | 39      | 113  | 157          | 682     | 1459    | 7103 | 21                    | 16      | 15      | 56   | 9770  |
| <b>2020</b> | 19              | 31      | 28      | 70   | 180          | 662     | 1353    | 7172 | 14                    | 9       | 9       | 44   | 9591  |
| <b>2021</b> | 25              | 34      | 40      | 84   | 156          | 656     | 1411    | 7134 | 13                    | 6       | 13      | 20   | 9592  |
| <b>2022</b> | 35              | 33      | 30      | 65   | 154          | 579     | 1359    | 7168 | 11                    | 7       | 7       | 16   | 9464  |

\*at first CD4 value

**3.4 Table: Treatment status of participants under follow-up, by HIV viral load and year \***

|             | Treatment naive (copies/ml) |          |              |         | On treatment (copies/ml) |          |              |         | Treatment interrupted (copies/ml) |          |              |         | Total |
|-------------|-----------------------------|----------|--------------|---------|--------------------------|----------|--------------|---------|-----------------------------------|----------|--------------|---------|-------|
|             | 0 - 50                      | 51 - 400 | 401 - 100000 | >100000 | 0 - 50                   | 51 - 400 | 401 - 100000 | >100000 | 0 - 50                            | 51 - 400 | 401 - 100000 | >100000 |       |
| <b>2017</b> | 58                          | 20       | 177          | 88      | 8859                     | 201      | 90           | 14      | 45                                | 11       | 45           | 12      | 9620  |
| <b>2018</b> | 56                          | 18       | 129          | 76      | 8953                     | 224      | 106          | 10      | 46                                | 15       | 39           | 10      | 9682  |
| <b>2019</b> | 46                          | 14       | 108          | 94      | 9053                     | 234      | 99           | 11      | 42                                | 11       | 40           | 13      | 9765  |
| <b>2020</b> | 36                          | 9        | 54           | 51      | 9019                     | 270      | 73           | 13      | 28                                | 9        | 25           | 14      | 9601  |
| <b>2021</b> | 50                          | 15       | 70           | 50      | 8976                     | 289      | 83           | 5       | 25                                | 2        | 13           | 13      | 9591  |
| <b>2022</b> | 33                          | 12       | 61           | 56      | 8837                     | 342      | 72           | 12      | 12                                | 4        | 16           | 9       | 9466  |

\*at first viral load in the reporting year

**3.5 Table: Participants under treatment by first, second and other regimen, median of the duration (days)**

| Treatment status | on first regimen |        | on second regimen |        | on third regimen |        | on fourth regimen |        | on fifth regimen |        | on ≥ sixth regimen |        | Total |
|------------------|------------------|--------|-------------------|--------|------------------|--------|-------------------|--------|------------------|--------|--------------------|--------|-------|
|                  | nb               | median | nb                | median | nb               | median | nb                | median | nb               | median | nb                 | median |       |
| <b>2017</b>      | 1275             | 1592   | 1456              | 1304   | 1196             | 1344.5 | 986               | 1250   | 867              | 1243   | 3403               | 1155   | 9183  |
| <b>2018</b>      | 994              | 1282.5 | 1495              | 962    | 1273             | 943    | 995               | 913    | 896              | 923    | 3667               | 855    | 9320  |
| <b>2019</b>      | 913              | 1087   | 1349              | 829    | 1343             | 752    | 1060              | 734    | 919              | 763    | 3834               | 716.5  | 9418  |
| <b>2020</b>      | 856              | 1022   | 1277              | 908    | 1285             | 785    | 1104              | 716    | 906              | 799    | 3959               | 722    | 9387  |
| <b>2021</b>      | 740              | 1212   | 1219              | 1096   | 1292             | 869    | 1185              | 792    | 908              | 840    | 3966               | 723    | 9310  |
| <b>2022</b>      | 707              | 1120   | 1147              | 1142   | 1267             | 941    | 1201              | 906    | 947              | 899    | 3981               | 853    | 9250  |

### 3.6 The most frequent combinations: reference January 1st, 2023

| REGIMEN         | nb   | %  |
|-----------------|------|----|
| BIC ETC TAF     | 2545 | 27 |
| 3TC DTG         | 1517 | 16 |
| ETC RPV TAF     | 843  | 9  |
| 3TC ABC DTG     | 748  | 8  |
| COB ETC EVG TAF | 581  | 6  |
| DTG ETC TAF     | 530  | 6  |
| CABI RPV        | 198  | 2  |
| ETC NVP TAF     | 197  | 2  |
| 3TC DOR TDF     | 191  | 2  |
| 3TC NVP         | 155  | 2  |
| Total           |      | 80 |

### 3.6.1 The most frequent combinations: reference July 1st, 2022

| REGIMEN         | nb   | %  |
|-----------------|------|----|
| BIC ETC TAF     | 2423 | 26 |
| 3TC DTG         | 1276 | 14 |
| 3TC ABC DTG     | 913  | 10 |
| ETC RPV TAF     | 899  | 10 |
| COB ETC EVG TAF | 707  | 8  |
| DTG ETC TAF     | 584  | 6  |
| ETC NVP TAF     | 207  | 2  |
| COB DRV ETC TAF | 168  | 2  |
| 3TC DOR TDF     | 166  | 2  |
| 3TC NVP         | 158  | 2  |
| Total           |      | 82 |

### 3.7 The most frequent initial regimens started in 2022

| REGIMEN             | nb  | %  |
|---------------------|-----|----|
| BIC ETC TAF         | 102 | 73 |
| DTG ETC TAF         | 7   | 5  |
| 3TC DTG             | 6   | 4  |
| COB DRV DTG ETC TAF | 6   | 4  |
| 3TC ABC DTG         | 3   | 2  |
| DTG ETC TDF         | 3   | 2  |
| Total               | 90  |    |

#### 3.7.1 The most frequent initial regimens started in 2021

| REGIMEN     | nb  | %  |
|-------------|-----|----|
| BIC ETC TAF | 126 | 74 |
| 3TC DTG     | 13  | 8  |
| DTG ETC TAF | 5   | 3  |
| 3TC ABC DTG | 4   | 2  |
| DTG ETC TDF | 4   | 2  |
| 3TC DOR TDF | 2   | 1  |
| Total       | 90  |    |

#### 3.7.2 The most frequent initial regimens started in 2020

| REGIMEN         | nb | %  |
|-----------------|----|----|
| BIC ETC TAF     | 91 | 71 |
| 3TC DTG         | 5  | 4  |
| COB ETC EVG TAF | 5  | 4  |
| DRV ETC RTV TAF | 4  | 3  |
| DTG ETC TAF     | 4  | 3  |
| 3TC ABC DTG     | 3  | 2  |
| Total           | 87 |    |

### 3.7.3 The most frequent initial regimens started in 2019

| REGIMEN             | nb | %  |
|---------------------|----|----|
| BIC ETC TAF         | 99 | 41 |
| DTG ETC TAF         | 64 | 27 |
| COB ETC EVG TAF     | 15 | 6  |
| 3TC ABC DTG         | 10 | 4  |
| COB DRV ETC EVG TAF | 9  | 4  |
| ETC RGV TDF         | 8  | 3  |
| Total               | 85 |    |

### 3.7.4 The most frequent initial regimens started in 2018

| REGIMEN             | nb | %  |
|---------------------|----|----|
| DTG ETC TAF         | 91 | 34 |
| COB ETC EVG TAF     | 51 | 19 |
| 3TC ABC DTG         | 42 | 16 |
| DTG ETC TDF         | 12 | 5  |
| DRV ETC RTV TAF     | 10 | 4  |
| DRV DTG ETC RTV TAF | 9  | 3  |
| Total               | 81 |    |

### 3.7.5 The most frequent initial regimens started in 2017

| REGIMEN         | nb | %  |
|-----------------|----|----|
| 3TC ABC DTG     | 85 | 27 |
| COB ETC EVG TAF | 70 | 22 |
| DTG ETC TAF     | 58 | 18 |
| DTG ETC TDF     | 23 | 7  |
| ETC RPV TDF     | 17 | 5  |
| EFV ETC TDF     | 11 | 3  |
| Total           | 82 |    |

**3.8 The most frequent treatment switches in 2022 (newly started treatments of treatment-experienced patients in 2022 listed)**

| REGIMEN     | nb  | %  |
|-------------|-----|----|
| 3TC DTG     | 521 | 31 |
| BIC ETC TAF | 391 | 23 |
| CABI RPV    | 198 | 12 |
| 3TC DOR TDF | 66  | 4  |
| 3TC ABC DTG | 40  | 2  |
| DTG ETC TAF | 40  | 2  |
| Total       | 74  |    |

**3.8.1 The most frequent treatment switches in 2021**

| REGIMEN     | nb  | %  |
|-------------|-----|----|
| BIC ETC TAF | 542 | 32 |
| 3TC DTG     | 541 | 32 |
| 3TC DOR TDF | 70  | 4  |
| ETC RPV TAF | 52  | 3  |
| 3TC ABC DTG | 38  | 2  |
| DTG ETC TAF | 37  | 2  |
| Total       | 75  |    |

**3.8.2 The most frequent treatment switches in 2020**

| REGIMEN         | nb   | %  |
|-----------------|------|----|
| BIC ETC TAF     | 1053 | 37 |
| ETC RPV TAF     | 329  | 12 |
| DTG ETC TAF     | 193  | 7  |
| 3TC ABC DTG     | 134  | 5  |
| COB DRV ETC TAF | 133  | 5  |
| 3TC NVP         | 118  | 4  |
| Total           | 70   |    |

### 3.8.3 The most frequent treatment switches in 2019

| REGIMEN         | nb  | %  |
|-----------------|-----|----|
| ETC RPV TAF     | 795 | 28 |
| DTG ETC TAF     | 464 | 16 |
| COB ETC EVG TAF | 289 | 10 |
| 3TC ABC DTG     | 238 | 8  |
| ETC RGV TAF     | 103 | 4  |
| DTG ETC         | 75  | 3  |
| Total           |     | 69 |

### 3.8.4 The most frequent treatment switches in 2018

| REGIMEN         | nb  | %  |
|-----------------|-----|----|
| COB ETC EVG TAF | 883 | 22 |
| DTG ETC TAF     | 747 | 18 |
| 3TC ABC DTG     | 386 | 9  |
| DRV ETC RTV TAF | 292 | 7  |
| ETC NVP TAF     | 276 | 7  |
| ETC RGV TAF     | 133 | 3  |
| Total           |     | 66 |

### 3.8.5 The most frequent treatment switches in 2017

| REGIMEN         | nb  | %  |
|-----------------|-----|----|
| 3TC ABC DTG     | 646 | 24 |
| COB ETC EVG TAF | 388 | 14 |
| DTG ETC TDF     | 234 | 9  |
| ETC RPV TDF     | 206 | 8  |
| DRV ETC RTV TDF | 75  | 3  |
| DTG             | 73  | 3  |
| Total           |     | 61 |

**3.9 The most frequent treatment switches in 2022/H2: From -> To**

| REGIMEN                        | nb  | %  |
|--------------------------------|-----|----|
| 3TC ABC DTG -> 3TC DTG         | 178 | 11 |
| BIC ETC TAF -> 3TC DTG         | 83  | 5  |
| COB ETC EVG TAF -> 3TC DTG     | 75  | 5  |
| COB ETC EVG TAF -> BIC ETC TAF | 68  | 4  |
| DTG ETC TAF -> 3TC DTG         | 56  | 3  |
| BIC ETC TAF -> CABI RPV        | 53  | 3  |
| 3TC ABC DTG -> BIC ETC TAF     | 50  | 3  |
| DTG ETC TAF -> BIC ETC TAF     | 41  | 3  |
| 3TC DTG -> CABI RPV            | 30  | 2  |
| Total                          | 39  |    |

**3.10.1 Table: The five most frequently discontinued regimens in 2017 by reason, number°**

|      |                 | Virological /<br>Immunological | Toxicity |       |        |     |       | Patient<br>wish | Physician<br>decision | Simplification | Other | No. of<br>regimen* |
|------|-----------------|--------------------------------|----------|-------|--------|-----|-------|-----------------|-----------------------|----------------|-------|--------------------|
|      |                 |                                | GI       | Liver | Kidney | CNS | Other |                 |                       |                |       |                    |
| 2017 | DTG ETC TDF     | 2                              | 2        | 3     | 28     | 7   | 14    | 9               | 68                    | 136            | 178   | 444                |
| 2017 | DRV ETC RTV TDF | 1                              | 0        | 0     | 31     | 2   | 15    | 15              | 45                    | 142            | 146   | 392                |
| 2017 | EFV ETC TDF     | 4                              | 3        | 2     | 20     | 47  | 33    | 8               | 50                    | 55             | 76    | 295                |
| 2017 | ETC NVP TDF     | 2                              | 1        | 3     | 10     | 0   | 9     | 3               | 23                    | 37             | 160   | 245                |
| 2017 | 3TC ABC DTG     | 3                              | 13       | 5     | 3      | 28  | 35    | 23              | 33                    | 5              | 87    | 234                |

**3.10.2 Table: The five most frequently discontinued regimens in 2018, by reason, number°**

|      |                 | Virological /<br>Immunological | Toxicity |       |        |     |       | Patient<br>wish | Physician<br>decision | Simplification | Other | No. of<br>regimen* |
|------|-----------------|--------------------------------|----------|-------|--------|-----|-------|-----------------|-----------------------|----------------|-------|--------------------|
|      |                 |                                | GI       | Liver | Kidney | CNS | Other |                 |                       |                |       |                    |
| 2018 | ETC RPV TDF     | 3                              | 1        | 1     | 38     | 3   | 13    | 11              | 164                   | 66             | 270   | 570                |
| 2018 | 3TC ABC DTG     | 2                              | 7        | 0     | 1      | 16  | 41    | 28              | 41                    | 16             | 100   | 252                |
| 2018 | EFV ETC TDF     | 1                              | 2        | 3     | 13     | 26  | 15    | 9               | 37                    | 40             | 66    | 212                |
| 2018 | DTG ETC TDF     | 0                              | 1        | 0     | 12     | 0   | 9     | 6               | 25                    | 18             | 50    | 120                |
| 2018 | COB ETC EVG TAF | 3                              | 4        | 1     | 1      | 11  | 7     | 19              | 22                    | 10             | 40    | 118                |

**3.10.3 Table: The five most frequently discontinued regimens in 2019, by reason, number°**

|      |                 | Virological /<br>Immunological | Toxicity |       |        |     |       | Patient<br>wish | Physician<br>decision | Simplification | Other | No. of<br>regimen* |
|------|-----------------|--------------------------------|----------|-------|--------|-----|-------|-----------------|-----------------------|----------------|-------|--------------------|
|      |                 |                                | GI       | Liver | Kidney | CNS | Other |                 |                       |                |       |                    |
| 2019 | 3TC ABC DTG     | 0                              | 7        | 0     | 1      | 15  | 59    | 28              | 81                    | 121            | 99    | 411                |
| 2019 | DTG ETC TAF     | 1                              | 0        | 1     | 2      | 7   | 8     | 26              | 59                    | 100            | 47    | 251                |
| 2019 | COB ETC EVG TAF | 3                              | 7        | 1     | 0      | 2   | 8     | 36              | 45                    | 64             | 81    | 247                |
| 2019 | EFV ETC TDF     | 2                              | 0        | 1     | 7      | 13  | 5     | 5               | 41                    | 32             | 49    | 155                |
| 2019 | ETC RPV TDF     | 1                              | 1        | 0     | 4      | 0   | 4     | 3               | 36                    | 10             | 83    | 142                |

**3.10.4 Table: The five most frequently discontinued regimens in 2020, by reason, number°**

|      |                 | Virological /<br>Immunological | Toxicity |       |        |     |       | Patient<br>wish | Physician<br>decision | Simplification | Other | No. of<br>regimen* |
|------|-----------------|--------------------------------|----------|-------|--------|-----|-------|-----------------|-----------------------|----------------|-------|--------------------|
|      |                 |                                | GI       | Liver | Kidney | CNS | Other |                 |                       |                |       |                    |
| 2020 | 3TC ABC DTG     | 1                              | 6        | 0     | 1      | 3   | 22    | 29              | 105                   | 101            | 76    | 344                |
| 2020 | DTG ETC TAF     | 2                              | 0        | 0     | 1      | 2   | 2     | 22              | 66                    | 97             | 35    | 227                |
| 2020 | COB ETC EVG TAF | 1                              | 2        | 1     | 3      | 2   | 4     | 12              | 19                    | 41             | 59    | 144                |
| 2020 | BIC ETC TAF     | 1                              | 4        | 0     | 1      | 4   | 12    | 23              | 12                    | 9              | 41    | 107                |
| 2020 | DRV ETC RTV TAF | 0                              | 0        | 0     | 0      | 0   | 2     | 2               | 18                    | 49             | 6     | 77                 |

**3.10.5 Table: The five most frequently discontinued regimens in 2021, by reason, number°**

|      |                 | Virological /<br>Immunological | Toxicity |       |        |     |       | Patient<br>wish | Physician<br>decision | Simplification | Other | No. of<br>regimen* |
|------|-----------------|--------------------------------|----------|-------|--------|-----|-------|-----------------|-----------------------|----------------|-------|--------------------|
|      |                 |                                | GI       | Liver | Kidney | CNS | Other |                 |                       |                |       |                    |
| 2021 | 3TC ABC DTG     | 1                              | 3        | 1     | 0      | 4   | 14    | 14              | 79                    | 167            | 71    | 354                |
| 2021 | BIC ETC TAF     | 2                              | 4        | 2     | 1      | 4   | 15    | 31              | 42                    | 44             | 108   | 253                |
| 2021 | COB ETC EVG TAF | 2                              | 1        | 0     | 1      | 0   | 4     | 9               | 39                    | 101            | 68    | 225                |
| 2021 | DTG ETC TAF     | 0                              | 1        | 0     | 0      | 0   | 2     | 17              | 46                    | 99             | 34    | 199                |
| 2021 | ETC RPV TAF     | 1                              | 1        | 0     | 0      | 1   | 5     | 8               | 20                    | 20             | 30    | 86                 |

**3.10.6 Table: The five most frequently discontinued regimens in 2022, by reason, number°**

|      |                 | Virological /<br>Immunological | Toxicity |       |        |     |       | Patient<br>wish | Physician<br>decision | Simplification | Other | No. of<br>regimen* |
|------|-----------------|--------------------------------|----------|-------|--------|-----|-------|-----------------|-----------------------|----------------|-------|--------------------|
|      |                 |                                | GI       | Liver | Kidney | CNS | Other |                 |                       |                |       |                    |
| 2022 | 3TC ABC DTG     | 2                              | 2        | 0     | 0      | 4   | 67    | 2               | 16                    | 142            | 63    | 298                |
| 2022 | BIC ETC TAF     | 4                              | 3        | 1     | 2      | 15  | 24    | 17              | 14                    | 95             | 94    | 269                |
| 2022 | COB ETC EVG TAF | 1                              | 1        | 0     | 1      | 1   | 32    | 6               | 27                    | 92             | 49    | 210                |
| 2022 | DTG ETC TAF     | 0                              | 2        | 0     | 0      | 1   | 5     | 4               | 14                    | 80             | 40    | 146                |
| 2022 | ETC RPV TAF     | 2                              | 2        | 0     | 2      | 0   | 4     | 4               | 12                    | 37             | 41    | 104                |

\*one regimen can have several reason for discontinuation

°the patients identity cannot be identified